Skip Navigation LinksHome > Professional Development > eLearning > Efficacy and Safety of Cryopreserved Platelets

Efficacy and Safety of Cryopreserved Platelets

Please note: AABB reserves the right to make updates to this program.

Wednesday, May 17, 2017
2:00 – 3:30 PM (ET) 7:00 – 8:30 PM (GMT)
Master Program Number: 136 (see program format numbers below under Registration)

Educational Track: Technical/Clinical
Topic: Transfusion Medicine
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors, Laboratory Staff, Medical Directors, Students/Fellows, Residents, Hospital Blood Banks
Teaching Level: Intermediate

Director/Moderator: Nancy M. Dunbar, MD, Medical Director, Blood Bank, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Speakers: Larry J. Dumont, MBA, PhD, Senior Investigator and Associate Director, Blood Systems Research Institute-Denver, Denver, CO;  Jose A. Cancelas, MD, PhD, Professor and Deputy Director, Hoxworth Blood Center, University of Cincinnati, Cincinnati, OH

Learning Objectives

After participating in this educational activity, participants should be able to:

  • Describe the preparation of cryopreserved platelets.
  • Assess the functionality of cryopreserved platelets based on in vitro laboratory studies.
  • Summarize findings of clinical studies evaluating the safety and efficacy of cryopreserved platelets.

Program Description

Research is underway to develop licensable platelet cryopreservation techniques to extend the five-day shelf life of platelets to more than two years. The research is sponsored by the U.S. Army and is currently in Phase 1 clinical trials. In this program, Drs. Dumont and Cancelas will describe the preparation of crypopreserved platelets, present in vitro data demonstrating the functionality of cryopreserved platelets and share preliminary results of ongoing clinical studies.

Registration

   Program #
Single Viewer: Live Register17EL-2035-136
Single Viewer: On-Demand Register17EL-4035-136
Group Viewing: Live Register17EL-6035-136
Group Viewing: On-Demand Register17EL-8035-136
Group Viewing: Live & On-Demand Register17EL-9935-136

Speaker Biographies

Dr. Larry Dumont received a bachelor’s degree in biology from Regis College, an MBA from the University of Phoenix and a doctorate in clinical sciences from the University of Colorado Health Sciences Center in Denver. He was a scientist and engineer in medical device manufacturing at Denver-based Gambro BCT (formerly COBE Laboratories, currently Terumo BCT) for 25 years and directed the Center for Transfusion Medicine Research at Geisel School of Medicine at Dartmouth from 2006-2016. At BSRI-Denver, Dr. Dumont is currently the Senior Investigator at Blood Systems Research Institute-Denver. In this role, he is working on a program to develop licensable platelet cryopreservation techniques that would be a game changer for providing platelets to patients. The program, currently in Phase 1 clinical trials, is sponsored by the U.S. Army and is expected to extend the five-day shelf life of platelets to more than two years.

Dr. Jose Cancelas received his MD and PhD from the Autonomous and Alcala de Henares Universities in Madrid (Spain) and specialized in Hematology and Transfusion Medicine in Madrid, Barcelona, Rotterdam and Cincinnati. He is the Deputy Director of Hoxworth Blood Center and Professor in the Cancer & Blood Diseases Institute, Dept. of Pediatrics of Cincinnati Children’s Hospital where he leads the Research Division and the Stem Cell Program, respectively.  His work for 23 years has been devoted to understanding basic concepts of blood cell biology and applying these concepts to the development of novel products in blood/cell therapies. At Hoxworth Blood Center, Dr. Cancelas has worked with Drs. Dumont and Slichter in the development of the phase 1 clinical trials on recovery/survival and safety in the treatment of bleeding patients of cryopreserved platelets, funded by the US Army. As a result of this team effort, sufficient data has been generated for the development of a phase 2 clinical trial to analyze the efficacy of cryopreserved platelets in bleeding patients.